Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Biopharmaceutics and Pharmacokinetics: Overview

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Healthcare worker access to molnupiravir: A case series.

PloS one·2023

Same author

Is It Time for Australia to Reassess Its Legislation on Human Embryo Experimentation?

Journal of law and medicine·2022

Same author

Does It Matter How We Die? Ethical and Legal Issues Raised by Combining Euthanasia and Organ Transplantation.

The Linacre quarterly·2020

Same author

Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?

Frontline gastroenterology·2017

Same author

Conscientious Objection in Health Care.

The New England journal of medicine·2017

Same author

CONVERTING THE 'RIGHT TO LIFE' TO THE 'RIGHT TO PHYSICIAN-ASSISTED SUICIDE AND EUTHANASIA': AN ANALYSIS OF CARTER V CANADA (ATTORNEY GENERAL), SUPREME COURT OF CANADA.

Medical law review·2016

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Developing a service for biologic therapies: a personal experience.

Margaret Somerville¹

¹Rheumatology Research Department, Norfolk and Norwich Health Care Trust, Brunswick Road, Norwich, Norfolk, UK.

Musculoskeletal Care

|March 11, 2010

Summary

Tumour necrosis factor alpha (TNFalpha) drives inflammation in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Targeting TNFalpha with biologic therapies offers a promising treatment strategy for these debilitating joint diseases.

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Related Experiment Videos

Last Updated: Jun 15, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Area of Science:

Rheumatology
Immunology
Pharmacology

Background:

Tumour necrosis factor alpha (TNFalpha) is implicated in the pathogenesis of synovitis and joint destruction in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Over-expression of pro-inflammatory cytokines like TNFalpha contributes to articular cartilage damage in rheumatic diseases.
Elevated TNFalpha levels correlate with disease activity in patients' serum and synovial fluid, identifying it as a therapeutic target.

Purpose of the Study:

To explore the development of a service for delivering biologic therapies targeting TNFalpha.
To outline the provision of advanced treatments for active RA and JIA.

Main Methods:

Review of existing literature on TNFalpha's role in RA and JIA pathogenesis.
Examination of approved and emerging biologic therapies (e.g., etanercept, infliximab, adalimumab, anakinra).
Service development framework for patient access to these treatments.

Main Results:

TNFalpha is a validated therapeutic target in RA and JIA.
Biologic agents like etanercept and infliximab are approved for active RA treatment.
Future availability of other biologic treatments is anticipated.

Conclusions:

Targeting TNFalpha is a viable strategy for managing RA and JIA.
The development of specialized services is crucial for effective patient access to biologic therapies.
Continued advancements in biologic treatments offer improved therapeutic options for rheumatic diseases.